Browse studies

Find your next paid study

27,377 recruiting studies available now

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or met…

Advanced Prostate CancerMetastatic Prostate Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Genentech, Inc.NCT05800665

Observational

Mindful Steps: Coupling Technology and Mind-Body Exercise to Facilitate Physical Activity in Chronic Cardiopulmonary Disease

The goal of this fully-remote randomized controlled trial is to test the efficacy of Mindful Steps in facilitating physical activity compared to usual standard…

Chronic Obstructive Pulmonary DiseaseChronic Heart Failure

Estimated

~$10 – $750

Actual pay is set by the research site.

Beth Israel Deaconess Medical CenterNCT05934565

Phase 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in ado…

Lupus Nephritis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Hoffmann-La RocheNCT05039619

Observational

Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions

The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage par…

Valvular Heart Disease

Estimated

~$10 – $750

Actual pay is set by the research site.

Vanderbilt University Medical CenterNCT06077201

Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products

Subjects exposed to gene therapy products (GTPs) may be at risk for delayed or long-term adverse events. This is a long-term follow-up (LTFU) protocol designed…

CAR T CellCAR T Cell Therapy

Estimated

~$10 – $750

Actual pay is set by the research site.

Seattle Children's HospitalNCT07424157

Phase 3

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who receiv…

Coronary Artery Disease (CAD)Coronary Artery Bypass Graft Surgery(CABG)

Estimated

~$50 – $2,250

Actual pay is set by the research site.

EBI Anti Sepsis BVNCT07357675

Phase 4

A Randomized Controlled Multicenter Trial, Examining the Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic fo…

Diabetic Foot Ulcer (DFU)Amnio-Maxx

Estimated

~$25 – $1,500

Actual pay is set by the research site.

Royal BiologicsNCT07209475

Phase 1

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

OverweightObesity

Estimated

~$500 – $11,250

Actual pay is set by the research site.

Novo Nordisk A/SNCT07767175

Phase 1

A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with …

Epidermal Growth FactorEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene Mutation+12 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Phase 2

Modulation of the Gut Microbiome by Dietary Fiber to Improve Calcium Absorption and Bone Health in Older Men

Osteoporotic fractures are a major but underrecognized problem in men. There is growing evidence that low dietary fiber intake is a modifiable risk factor for …

Aging

Estimated

~$75 – $1,800

Actual pay is set by the research site.

VA Office of Research and DevelopmentNCT06519877

Phase 2

A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.

This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with me…

Pancreatic Ductal Adenocarcinoma (mPDAC)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of California, San DiegoNCT06790602

Elucidation of Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide (PTCy) as a Strategy for Graft Versus Host Disease Prevention in Haploidentical, Matched Related Donor and Matched Unrelated Donor Peripheral Blood Hematopoietic Cell Transplantation

This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a t…

Leukemia, Not Otherwise SpecifiedLeukemia, Other

Estimated

~$10 – $750

Actual pay is set by the research site.

Wake Forest University Health SciencesNCT03555851